08:02 AM EDT, 10/16/2024 (MT Newswires) -- Merck ( MRK ) said Wednesday that the late-stage trial of its vaccine, Capvaxive, showed positive immune responses in adults at high risk for pneumococcal disease.

The results of the trial were presented at the IDWeek 2024 in Los Angeles, California, the drugmaker said.

The trial evaluated Capvaxive's immunogenicity, safety, and tolerability in vaccine-naive adults aged 18 to 64 with high risk for pneumococcal disease.

The study included 518 participants who were randomized 3-to-1 to receive Capvaxive or a combination of pneumococcal 15-valent conjugate vaccine, PCV15, and pneumococcal 23-valent polysaccharide vaccine, PPSV23.

Merck ( MRK ) said the trial found that Capvaxive was immunogenic for all 21 serotypes, with immune responses comparable to PCV15 + PPSV23 for the 13 common serotypes and higher for the eight unique to Capvaxive.

In addition, adverse events, including injection-site and systemic reactions, were numerically lower in the Capvaxive group compared to PCV15 + PPSV23.

Price: 111.38, Change: -0.15, Percent Change: -0.13